[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

The Assessment Group: Market Research Reports

Established in 2001 by academic researchers, The Assessment Group is now an independent company delivering high-quality assessment services for a slew of pharmaceutical and biotech companies, and many more institutions involved in the healthcare industry. The firm’s core business is to prepare comprehensive practice pattern evaluations for healthcare sector marketing initiatives.

The Assessment Group’s offerings identify and evaluate the impact of promotional activities, which have influence on management and treatment decisions. The Assessment Group is recognized for the provisioning of high-quality, objective and efficient assessments. It elaborates and offers both custom-built and ready-made reports. The firm equips clients with the unparalleled solution focused impact metrics.

The reports prepared by The Assessment Group uncover essential data on the modern physician practice patterns, provide detailed discussions of various clinical decisions along with comprehensive analyses of the forces influencing them, examine key challenges to patient care, and unveil relevant information required to elaborate efficient market strategies leading to fruitful results.

Publications found: 22
Sort by:
US Market Changes in the Treatment of Advanced Prostate Cancer US$ 2,900.00

Progressively unfolding patient case scenarios were presented to 151 U.S. oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence ...

September 2012 30 pages
US Market Changes in the Treatment of Advanced Melanoma US$ 2,900.00

... regimen choices, factors that influence their decisions, barriers to optimal patient care and confidence in patient treatment. This report identifies market changes based on a comparison of physician practice patterns from 2011 and 2012 and provides actionable data for developing marketing strategies.

September 2012 31 pages
US Market Changes in the Treatment of Advanced Breast Cancer US$ 2,900.00

... of treatment regimens, factors that influenced their decisions, barriers to optimal patient treatment and confidence in treatment and management of patients. This survey was conducted in 2011 and 2012 to determine trends across time and changes in practice patterns in the management of advanced breast cancer.

September 2012 34 pages
US Market Changes in the Treatment of Advanced Lung Cancer US$ 2,900.00

The purpose of this study is to examine changes in the market for therapeutics used in the treatment of advanced lung cancer by examining longitudinal practice patterns of oncologists. Progressively unfolding patient case scenarios were presented to 152 U.S. oncologists for their responses to open-ended ...

September 2012 39 pages
US Market Changes in the Treatment of Non-Hodgkin's Lymphoma US$ 2,900.00

... factors that influenced their decisions, barriers to optimal patient treatment and confidence in treatment and management of patients. This survey was conducted in 2011 and 2012 using parallel cases to determine trends across time and changes in practice patterns in the management of non-Hodgkin’s lymphoma.

September 2012 46 pages
Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists' Survey US$ 500.00

... patient specific case scenario on advanced lung cancer in a situation involving a smoker with squamous cell that progresses throughout the report, presented ... cancer. This report allows you to: Understand what occurs with actual patients Access the most up-to-date prescribing trends Gain actionable data ...

April 2011 25 pages
Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma: Clinical Insights from a US Oncologists' Survey US$ 500.00

A patient specific case scenario on advanced lung cancer in a situation involving a patient with EGFR Mutation Positive Adenocarcinoma that progresses throughout the ... that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in ...

April 2011 33 pages
Advanced Lung Cancer in Patient Light Smoker with Lung Adenocarcinoma: Clinical Insights from a US Oncologists' Survey US$ 2,999.00

Global Site License Price: US$ 4,999.00 A patient specific case scenario on advanced lung cancer in a situation involving a patient that is a light smoker with lung adenocarcinoma that progresses thro...

April 2011 28 pages
US Oncologist Survey: Optimizing Treatment for Advanced Lung Cancer US$ 1,200.00

... to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment ... with adenocarcinoma Former light smoker whose cancer is EGFR positive Treatment decisions for advanced stages of cancer are difficult to track as information ...

April 2011 56 pages
US Oncologist Survey: Optimizing Treatment for Stage IIIA Asymptomatic Indolent Lymphoma US$ 500.00

... decisions Barriers to optimal patient care Confidence in treatment Data has been synthesized to show all responses and direct quotes from the oncologists. ... with the introduction of new products that all have an impact oncologists’ choices. This report is part of a series of oncology reports that allow ...

April 2011 28 pages
US Oncologist Survey: Optimizing Treatment for Large Cell Lymphoma US$ 500.00

... that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal ... Barriers to optimal patient care Confidence in treatment Data has been synthesized to show all responses and direct quotes from the oncologists ...

April 2011 35 pages
US Oncologist Survey: Optimizing Treatment for Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma US$ 500.00

... that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal ... Barriers to optimal patient care Confidence in treatment Data has been synthesized to show all responses and direct quotes from the oncologists ...

April 2011 26 pages
US Oncologist Survey: Optimizing Treatment for Advanced Non-Hodgkin's Lymphoma US$ 1,200.00

... . This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of specific patient types. Patient situations: Asymptomatic indolent lymphoma Elderly infirm patient with advanced follicular lymphoma Relapsed ...

April 2011 61 pages
Advanced Prostate Cancer with Increased PSA and Adenocarcinoma: Clinical Insights from a US Oncologists' Survey US$ 500.00

... prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of patients with advanced prostate cancer. Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and ...

March 2011 35 pages
Castration Resistant Prostate Cancer: Clinical Insights from a US Oncologists' Survey US$ 500.00

... for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment and testing choices, factors ... are missing, directly from high-prescribing US oncologists on the treatment of patients with advanced prostate cancer. Treatment decisions for advanced stages ...

March 2011 24 pages
US Oncologist Survey: Optimizing Treatment for Advanced Prostate Cancer US$ 1,200.00

... that unfold throughout the report, presented to 119 high-prescribing oncologists on Metastatic Clear Cell Renal Cell Cancer for their open ... , barriers to optimal care, and confidence in treatment. Patients include: Patient case scenarios that progressively unfold, presented to 154 oncologists in a survey for ...

March 2011 52 pages
Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer US$ 500.00

Treatment decisions for advanced stages of renal cell cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening ...

February 2011 59 pages
US Oncologist Survey: Optimizing Treatment for Metastatic Clear Cell Renal Cell Carcinoma US$ 500.00

... that unfold throughout the report, presented to 119 high-prescribing oncologists on Metastatic Clear Cell Renal Cell Cancer for their open ... , barriers to optimal care, and confidence in treatment. Patients include: Patient case scenarios that progressively unfold, presented to 154 oncologists in a survey for ...

February 2011 29 pages
US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer US$ 1,200.00

Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at ...

January 2011 59 pages
Triple Negative Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey US$ 500.00

... patient case scenario that unfolds throughout the report, presented to high-prescribing oncologists on Triple Negative Metastatic Breast Cancer for their clinical decisions. Out of 174 oncologists’ responses, those who use combination chemotherapy were most likely to use xx and ...

January 2011 36 pages
Triple Positive Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey US$ 500.00

... the report, presented to 174 high-prescribing oncologists on Triple Positive Metastatic Breast Cancer for their open responses on clinical decisions. Patient ... the report, presented to 119 high-prescribing oncologists on Metastatic Clear Cell Renal Cell Cancer for their open responses on clinical decisions. ...

January 2011 30 pages
US Oncologist Survey: Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer US$ 500.00

... that unfold throughout the report, presented to 119 high-prescribing oncologists on Metastatic Clear Cell Renal Cell Cancer for their open ... , barriers to optimal care, and confidence in treatment. Patients include: Patient case scenarios that progressively unfold, presented to 154 oncologists in a survey for ...

January 2011 31 pages

Filters

Search

Categories

5
17

Publishers

22

Regions

11
11

Price

Date

Pages

Offers